According to a recent study, subcutaneous maintenance dosing of risankizumab at 52 weeks is effective and well-tolerated in patients with moderate-to-severe Crohn disease who had a delayed response to...
The authors of a new study presented at the ACG 2019 Annual Meeting evaluated data of more than 200 adult gastroenterology patients to characterize patients with avoidant/restrictive food intake disorder. ...
